📇 Rhumatologue · LE MANS CEDEX 9 · (72) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
20 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
77.4 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
16
16 articles ont été cités au moins 16fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 335
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
81
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
24
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier du Mans
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
IRF4 haploinsufficiency in a multiplex family with Whipple’s disease
2026ArticleJournal of Human Immunity
Development and validation of the FIP-Score for the screening of FIP1L1::PDGFRA-associated hypereosinophilic syndrome
2025ArticleJournal of Allergy and Clinical Immunology: In Practice
Experiences of telehealth during and after the COVID-19 pandemic and preferences for future care of people with systemic sclerosis: a cross-sectional study
2024ArticleThe Lancet Rheumatology
Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2024ArticleGenome Medicine
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2023ArticleGenome Medicine
Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes
2023ArticleRheumatology
Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses
2022ArticleRheumatology
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
2022ArticleThe Lancet Rheumatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CENTRE HOSPITALIER DU MANS
194 AV RUBILLARD, 72037 LE MANS CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMJ (Clinical research ed.) · 2020
Abstract Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design Comparative observational study using data collected from routine care. Setting Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. Participants 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. Interventions Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). Main outcome measures The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. Conclusions Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.
Autoimmunity reviews · 2020
Autoimmunity reviews · 2017
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Kidney international reports · 2025 · Journal Article
Kante A, Legendre P, Joly BS, Dunogué B, et al.
Journal of scleroderma and related disorders · 2021 · Journal Article
Furtado S, Dunogué B, Jourdi G, Chaigne B, et al.
Journal of scleroderma and related disorders · 2021 · Journal Article
Legendre P, Blanchet B, Porcher R, Bérezné A, et al.
Autoimmunity reviews · 2020 · Journal Article
Terrier B, Humbert S, Preta LH, Delage L, et al.
Autoimmunity reviews · 2019 · Journal Article
Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L
Journal of internal medicine · 2026 · Journal Article
Pallotti F, Mettler C, Papo M, Iudici M, et al.
BMJ case reports · 2025 · Journal Article
Trochain J, Moscovici C, Le Nezet M, Legendre P
International journal of surgical pathology · 2024 · Case Reports
Baber A, Legendre P, Palmic P, Lupo-Mansuet A, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
BMJ (Clinical research ed.) · 2020 · Journal Article
Mahévas M, Tran VT, Roumier M, Chabrol A, et al.
Autoimmunity reviews · 2017 · Journal Article
Legendre P, Régent A, Thiebault M, Mouthon L
Anaerobe · 2016 · Case Reports
Legendre P, Lalande V, Eckert C, Barbut F, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
Anaerobe · 2016 · Case Reports
Legendre P, Lalande V, Eckert C, Barbut F, et al.
Ocular immunology and inflammation · 2023 · Journal Article
Martellosio JP, Gastli N, Farhat R, Tazi A, et al.
Kidney international reports · 2025 · Journal Article
Kante A, Legendre P, Joly BS, Dunogué B, et al.
Rheumatology (Oxford, England) · 2021 · Case Reports
Régent A, Terrier B, Legendre P, Wartski M, et al.
Neurogastroenterology and motility · 2022 · Journal Article
Benech N, Legendre P, Radoszycki L, Varriale P, et al.
Therapeutic drug monitoring · 2021 · Journal Article
Chouchana L, Boujaafar S, Gana I, Preta LH, et al.
Autoimmunity reviews · 2017 · Journal Article
Legendre P, Régent A, Thiebault M, Mouthon L
Lupus · 2020 · Case Reports
Stammler R, Legendre P, Cacoub P, Blanche P, et al.
JAMA dermatology · 2025 · Journal Article
Breillat P, Le Guern V, d'Humières T, Battistella M, et al.
High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications
Objective:To determine the frequency of elevated D-dimer plasma concentration (>500 ng/mL) in patients with systemic sclerosis and evaluate its association with systemic sclerosis–specific microvascular and macrovascu
Supplementalfigure2 – Supplemental material for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Supplemental material, Supplementalfigure2 for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Objective:To explore pharmacokinetic/pharmacodynamic relationship between mycophenolic acid area under the curve and clinical response at 1 year on skin involvement or interstitial lung disease in patients with systemic
NBSupplementalfigure3 – Supplemental material for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Supplemental material, NBSupplementalfigure3 for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French stu
NBSupplementalfigure3 – Supplemental material for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Supplemental material, NBSupplementalfigure3 for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French stu
Supplementalfigure2 – Supplemental material for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Supplemental material, Supplementalfigure2 for Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
European journal of dermatology : EJD · 2018 · Case Reports
Legendre P, Norkowski E, Le Pelletier F, Miyara M, et al.
International journal of tissue reactions · 1988 · Journal Article
Legendre P, Daireaux M, Langris M, Pujol JP, et al.